ClinicalTrials.gg

Program

Lithium

Also written as “lithium” and “lithium (mood stabilizer)”.

Its studies are mostly in Bipolar Disorder · Mania · Alcoholism, led by 3 companies.

Furthest: phase 4, since Jun 29, 200910 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca50 open or runningphase 4since Jun 29, 2009Apr 9, 2004none ahead
Hikma Pharmaceuticals40 open or runningno phasesince Sep 19, 2007Sep 19, 2007none ahead
Bristol-Myers Squibb10 open or runningphase 1since Dec 9, 2024Dec 9, 2024none ahead

Also a collaborator on its studies: quintiles-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 9, 2004First study: phase 3 study in Bipolar DisorderNew to AstraZenecaAstraZeneca · NCT00081380 · 710 enrolled · United States, Canada
  2. Apr 7, 2005Phase 3 study in Bipolar DisorderAstraZeneca · NCT00107731 · 710 enrolled · United States, Australia, Belgium and more
  3. Jun 16, 2005Phase 3 study in AlcoholismAstraZeneca · NCT00114686 · 350 enrolled · United States
  4. Mar 16, 2007Phase 3 study in ManiaAstraZeneca · NCT00448578 · 150 enrolled · China
  5. Sep 19, 2007Hikma Pharmaceuticals's first studies: 2 no phase studies in Bipolar DisorderNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT00602381, NCT00601575
  6. Jan 15, 20082 no phase studies in Bipolar DisorderHikma Pharmaceuticals · NCT00602394, NCT00601536
  7. Jun 29, 2009Phase 4 study in ManiaAstraZeneca · NCT00931723 · 356 enrolled · Belgium, Bulgaria, Germany and more
  8. Dec 9, 2024Bristol-Myers Squibb's first study: phase 1 study in Healthy VolunteersNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT06729970 · 133 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06729970Healthy Volunteers · United States1CompletedBristol-Myers SquibbJan 23, 2026133
NCT00931723Mania · Belgium, Bulgaria, Germany and more4CompletedAstraZenecaNov 2010356
NCT00602394Bipolar Disorder · United States–CompletedHikma PharmaceuticalsMay 200330
NCT00601536Bipolar Disorder · United States–CompletedHikma PharmaceuticalsMay 200329
NCT00602381Bipolar Disorder · United States–CompletedHikma PharmaceuticalsNov 200230
NCT00601575Bipolar Disorder · United States–CompletedHikma PharmaceuticalsOct 200230
NCT00448578Mania · China3CompletedAstraZeneca150
NCT00114686Alcoholism · United States3CompletedAstraZeneca350
NCT00107731Bipolar Disorder · United States, Australia, Belgium and more3CompletedAstraZeneca710
NCT00081380Bipolar Disorder · United States, Canada3CompletedAstraZeneca710

How it is read

Names in the registry

  • “Lithium”, 7 entries
  • “lithium”, 2 entries
  • “lithium (mood stabilizer)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.